CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 83 enrolled
Drug / intervention
Naltrexone +1 moredrug
Likely dose
Naltrexone 50 mg/day, 100 mg/day, or 150 mg/dayAI-extracted
Key inclusion· 5
  • ✓Diagnostic and Statistical Manual IV criteria for Pathological Gambling Disorder
  • ✓Moderate or severe gambling urge assessed by the Gambling Symptom Assessment Scale
  • ✓No psychiatric drug use for 2 weeks or more
  • ✓Score >= 5 on The South Oaks Gambling Screen
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00053677
NCT00053677Phase 3Completed
CompareCT.gov

Naltrexone Treatment in Pathologic Gambling Disorder

University of Chicago·interventional·Posted Feb 5, 2003·Updated Feb 23, 2023

In Brief

A Phase 3 clinical trial evaluating Naltrexone and Placebo for Gambling. Completed, enrolled 83 participants across 1 site.

Detailed Summary

This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGambling
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 5, 2003
Enrollment StartDec 1, 2002
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 23.4 years ago

Interventions

Naltrexonedrug

For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.

Placebodrug

For subjects who were randomly assigned to placebo.